Breaking News, Collaborations & Alliances

Kamada Signs Supply Agreement with Israeli Health Authorities

Will provide investigational Covid-19 plasma-derived Immunoglobulin.

By: Contract Pharma

Contract Pharma Staff

The Israeli health authorities have signed a supply agreement for the investigational Covid-19 plasma-derived Immunoglobulin (IgG), to be supplied by Kamada Ltd., a biopharmaceutical company which is partnered with Kedrion Biopharma in the development of the new anti-Covid-19 therapy.    The Israeli company will manufacture the product, to be supplied to the Ministry of Health, from convalescent plasma collected by the Israeli National Blood Services, a division of Magen David Adom (MADA), and a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters